CytomX director granted 59,000 stock options
CytomX Therapeutics director Alan Ashworth received a grant of stock options covering 59,000 shares of common stock.
Rhea-AI Filing Summary
CytomX Therapeutics director Alan Ashworth received a grant of stock options covering 59,000 shares of common stock. The options have an exercise price of $2.96 per share and expire on June 16, 2036.
According to the terms, 100% of the shares subject to the option will vest on the earlier of the first anniversary of the grant date or the 2027 annual meeting of stockholders, assuming he continues to serve as a director through that date. Following this grant, he holds options for 59,000 shares directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 59,000 shares
Grant/Award
1 txn
Insider
Ashworth Alan
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 59,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 59,000 contracts (Direct)
Footnotes (1)
- F1. 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.
Key Figures
Option grant size: 59,000 options
Exercise price: $2.96 per share
Underlying shares: 59,000 shares
+2 more
5 metrics
Option grant size
59,000 options
Stock Option (Right to Buy) granted to director
Exercise price
$2.96 per share
Strike price of stock option grant
Underlying shares
59,000 shares
Common stock underlying the options
Expiration date
June 16, 2036
Option expiration
Post-grant derivative holdings
59,000 options
Total options held following transaction
Key Terms
Stock Option (Right to Buy), grant/award acquisition, exercise price, expiration date, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
grant/award acquisition financial
"transaction_action: grant/award acquisition"
exercise price financial
"conversion_or_exercise_price: 2.9600"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-06-16T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
Annual Meeting of the Issuer's stockholders financial
"the date of the 2027 Annual Meeting of the Issuer's stockholders"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Alan Ashworth acquire in this CytomX (CTMX) Form 4 filing?
Alan Ashworth received a grant of stock options for 59,000 shares of CytomX common stock. These options give him the right to buy shares at a fixed price if they vest and are exercised.
What is the exercise price of Alan Ashworth’s new CytomX (CTMX) stock options?
The stock options have an exercise price of $2.96 per share. This is the price at which he can buy CytomX common shares once the options vest and if he chooses to exercise them.
When do Alan Ashworth’s CytomX (CTMX) stock options vest?
All 59,000 option shares vest in full on the earlier of the first anniversary of the grant date or the 2027 annual stockholders’ meeting. Vesting requires his continuous service as a director through that date.
When do Alan Ashworth’s CytomX (CTMX) stock options expire?
The options expire on June 16, 2036. After this expiration date, any unexercised portion of the 59,000 options will lapse and can no longer be used to purchase CytomX shares.
How many CytomX (CTMX) derivative securities does Alan Ashworth hold after this grant?
Following this grant, Alan Ashworth holds stock options covering 59,000 shares of CytomX common stock. These options represent a right to acquire shares in the future at the $2.96 exercise price.
Is Alan Ashworth’s CytomX (CTMX) option grant an open-market purchase or compensation?
The Form 4 identifies the transaction as a grant or award acquisition, not an open-market purchase. It represents equity compensation for his role as a director, with vesting tied to continued board service.
AI-generated analysis. How Rhea-AI works. Not financial advice.
